Global Retinal Vascular Occlusion 麻豆原创 Research Report 2023

Publication ID:

PB502232777

Publication Date:

February 6, 2023

Pages:

Publisher:

MRRPB5

Countries:

Global [1]

USD 2,900.00

Pharmaceutical Manufacturing [2]

Healthcare [3]

Pharma & Healthcare [4]

Description:

Retinal Vascular Occlusion (RVO) is the build-up of blood or other fluids in the retina of the eye, which prevents it from properly filtering light caused by the blood clot.
Highlights
The global Retinal Vascular Occlusion market was valued at US$ million in 2022 and is anticipated to reach US$ million by 2029, witnessing a CAGR of % during the forecast period 2023-2029. The influence of COVID-19 and the Russia-Ukraine War were considered while estimating market sizes.
The Americas account for a significant market share owing to high expenditure on the health care, especially, of the U.S. and Canada. Additionally, the greater number of ophthalmology procedures due to greater healthcare penetration in the U.S. and Canada drives the retinal vascular occlusion market. The high concentration of the major hospitals in the developed countries of this region coupled with good reimbursement rates is adding fuel to the market growth. Moreover, the large share of ophthalmology procedures, especially, the retinal vascular occlusion surgery treatment in the returns of hospitals favors the market. The large number of pharmaceutical companies in the U.S. is also a cause for the faster development of retinal vascular occlusion market in the US. The high development of the microsurgery field in developed regions such as the U.S. and Europe is a strong driver of the market.
Report Scope
This report aims to provide a comprehensive presentation of the global market for Retinal Vascular Occlusion, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Retinal Vascular Occlusion.
The Retinal Vascular Occlusion market size, estimations, and forecasts are provided in terms of and revenue ($ millions), considering 2022 as the base year, with history and forecast data for the period from 2018 to 2029. This report segments the global Retinal Vascular Occlusion market comprehensively. Regional market sizes, concerning products by type, by application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Retinal Vascular Occlusion companies, new entrants, and industry chain related companies in this market with information on the revenues for the overall market and the sub-segments across the different segments, by company, by type, by application, and by regions.
By Company
Regeneron Pharmaceuticals, Inc.
Bayer HealthCare Pharmaceuticals LLC.
Novartis AG
Pfizer, Inc.
AstraZeneca PLC.
GlaxoSmithKline PLC.
Johnson & Johnson
Teva pharmaceutical industries
Novo Nordisk
Sanofi
Segment by Type
Anti-vascular Endothelial Growth Factor (VEGF)
Corticosteroid
Anticoagulants
Fibrinolytic
Others
Segment by Application
Hospitals and Clinics
Research and Academics
Others
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Core Chapters
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Retinal Vascular Occlusion companies鈥� competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the key companies in the market in detail, including product revenue, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.

Please Note - This is an on demand report and will be delivered in 2 business days (48 hours) post payment.

Table Of Contents:

1 Report Overview
1.1 Study Scope
1.2 麻豆原创 Analysis by Type
1.2.1 Global Retinal Vascular Occlusion 麻豆原创 Size Growth Rate by Type: 2018 VS 2022 VS 2029
1.2.2 Anti-vascular Endothelial Growth Factor (VEGF)
1.2.3 Corticosteroid
1.2.4 Anticoagulants
1.2.5 Fibrinolytic
1.2.6 Others
1.3 麻豆原创 by Application
1.3.1 Global Retinal Vascular Occlusion 麻豆原创 Growth by Application: 2018 VS 2022 VS 2029
1.3.2 Hospitals and Clinics
1.3.3 Research and Academics
1.3.4 Others
1.4 Study Objectives
1.5 Years Considered
1.6 Years Considered
2 Global Growth Trends
2.1 Global Retinal Vascular Occlusion 麻豆原创 Perspective (2018-2029)
2.2 Retinal Vascular Occlusion Growth Trends by Region
2.2.1 Global Retinal Vascular Occlusion 麻豆原创 Size by Region: 2018 VS 2022 VS 2029
2.2.2 Retinal Vascular Occlusion Historic 麻豆原创 Size by Region (2018-2023)
2.2.3 Retinal Vascular Occlusion Forecasted 麻豆原创 Size by Region (2024-2029)
2.3 Retinal Vascular Occlusion 麻豆原创 Dynamics
2.3.1 Retinal Vascular Occlusion Industry Trends
2.3.2 Retinal Vascular Occlusion 麻豆原创 Drivers
2.3.3 Retinal Vascular Occlusion 麻豆原创 Challenges
2.3.4 Retinal Vascular Occlusion 麻豆原创 Restraints
3 Competition Landscape by Key Players
3.1 Global Top Retinal Vascular Occlusion Players by Revenue
3.1.1 Global Top Retinal Vascular Occlusion Players by Revenue (2018-2023)
3.1.2 Global Retinal Vascular Occlusion Revenue 麻豆原创 Share by Players (2018-2023)
3.2 Global Retinal Vascular Occlusion 麻豆原创 Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by Retinal Vascular Occlusion Revenue
3.4 Global Retinal Vascular Occlusion 麻豆原创 Concentration Ratio
3.4.1 Global Retinal Vascular Occlusion 麻豆原创 Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Retinal Vascular Occlusion Revenue in 2022
3.5 Retinal Vascular Occlusion Key Players Head office and Area Served
3.6 Key Players Retinal Vascular Occlusion Product Solution and Service
3.7 Date of Enter into Retinal Vascular Occlusion 麻豆原创
3.8 Mergers & Acquisitions, Expansion Plans
4 Retinal Vascular Occlusion Breakdown Data by Type
4.1 Global Retinal Vascular Occlusion Historic 麻豆原创 Size by Type (2018-2023)
4.2 Global Retinal Vascular Occlusion Forecasted 麻豆原创 Size by Type (2024-2029)
5 Retinal Vascular Occlusion Breakdown Data by Application
5.1 Global Retinal Vascular Occlusion Historic 麻豆原创 Size by Application (2018-2023)
5.2 Global Retinal Vascular Occlusion Forecasted 麻豆原创 Size by Application (2024-2029)
6 North America
6.1 North America Retinal Vascular Occlusion 麻豆原创 Size (2018-2029)
6.2 North America Retinal Vascular Occlusion 麻豆原创 Growth Rate by Country: 2018 VS 2022 VS 2029
6.3 North America Retinal Vascular Occlusion 麻豆原创 Size by Country (2018-2023)
6.4 North America Retinal Vascular Occlusion 麻豆原创 Size by Country (2024-2029)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Retinal Vascular Occlusion 麻豆原创 Size (2018-2029)
7.2 Europe Retinal Vascular Occlusion 麻豆原创 Growth Rate by Country: 2018 VS 2022 VS 2029
7.3 Europe Retinal Vascular Occlusion 麻豆原创 Size by Country (2018-2023)
7.4 Europe Retinal Vascular Occlusion 麻豆原创 Size by Country (2024-2029)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Retinal Vascular Occlusion 麻豆原创 Size (2018-2029)
8.2 Asia-Pacific Retinal Vascular Occlusion 麻豆原创 Growth Rate by Region: 2018 VS 2022 VS 2029
8.3 Asia-Pacific Retinal Vascular Occlusion 麻豆原创 Size by Region (2018-2023)
8.4 Asia-Pacific Retinal Vascular Occlusion 麻豆原创 Size by Region (2024-2029)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America Retinal Vascular Occlusion 麻豆原创 Size (2018-2029)
9.2 Latin America Retinal Vascular Occlusion 麻豆原创 Growth Rate by Country: 2018 VS 2022 VS 2029
9.3 Latin America Retinal Vascular Occlusion 麻豆原创 Size by Country (2018-2023)
9.4 Latin America Retinal Vascular Occlusion 麻豆原创 Size by Country (2024-2029)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Retinal Vascular Occlusion 麻豆原创 Size (2018-2029)
10.2 Middle East & Africa Retinal Vascular Occlusion 麻豆原创 Growth Rate by Country: 2018 VS 2022 VS 2029
10.3 Middle East & Africa Retinal Vascular Occlusion 麻豆原创 Size by Country (2018-2023)
10.4 Middle East & Africa Retinal Vascular Occlusion 麻豆原创 Size by Country (2024-2029)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 Regeneron Pharmaceuticals, Inc.
11.1.1 Regeneron Pharmaceuticals, Inc. Company Detail
11.1.2 Regeneron Pharmaceuticals, Inc. Business Overview
11.1.3 Regeneron Pharmaceuticals, Inc. Retinal Vascular Occlusion Introduction
11.1.4 Regeneron Pharmaceuticals, Inc. Revenue in Retinal Vascular Occlusion Business (2018-2023)
11.1.5 Regeneron Pharmaceuticals, Inc. Recent Development
11.2 Bayer HealthCare Pharmaceuticals LLC.
11.2.1 Bayer HealthCare Pharmaceuticals LLC. Company Detail
11.2.2 Bayer HealthCare Pharmaceuticals LLC. Business Overview
11.2.3 Bayer HealthCare Pharmaceuticals LLC. Retinal Vascular Occlusion Introduction
11.2.4 Bayer HealthCare Pharmaceuticals LLC. Revenue in Retinal Vascular Occlusion Business (2018-2023)
11.2.5 Bayer HealthCare Pharmaceuticals LLC. Recent Development
11.3 Novartis AG
11.3.1 Novartis AG Company Detail
11.3.2 Novartis AG Business Overview
11.3.3 Novartis AG Retinal Vascular Occlusion Introduction
11.3.4 Novartis AG Revenue in Retinal Vascular Occlusion Business (2018-2023)
11.3.5 Novartis AG Recent Development
11.4 Pfizer, Inc.
11.4.1 Pfizer, Inc. Company Detail
11.4.2 Pfizer, Inc. Business Overview
11.4.3 Pfizer, Inc. Retinal Vascular Occlusion Introduction
11.4.4 Pfizer, Inc. Revenue in Retinal Vascular Occlusion Business (2018-2023)
11.4.5 Pfizer, Inc. Recent Development
11.5 AstraZeneca PLC.
11.5.1 AstraZeneca PLC. Company Detail
11.5.2 AstraZeneca PLC. Business Overview
11.5.3 AstraZeneca PLC. Retinal Vascular Occlusion Introduction
11.5.4 AstraZeneca PLC. Revenue in Retinal Vascular Occlusion Business (2018-2023)
11.5.5 AstraZeneca PLC. Recent Development
11.6 GlaxoSmithKline PLC.
11.6.1 GlaxoSmithKline PLC. Company Detail
11.6.2 GlaxoSmithKline PLC. Business Overview
11.6.3 GlaxoSmithKline PLC. Retinal Vascular Occlusion Introduction
11.6.4 GlaxoSmithKline PLC. Revenue in Retinal Vascular Occlusion Business (2018-2023)
11.6.5 GlaxoSmithKline PLC. Recent Development
11.7 Johnson & Johnson
11.7.1 Johnson & Johnson Company Detail
11.7.2 Johnson & Johnson Business Overview
11.7.3 Johnson & Johnson Retinal Vascular Occlusion Introduction
11.7.4 Johnson & Johnson Revenue in Retinal Vascular Occlusion Business (2018-2023)
11.7.5 Johnson & Johnson Recent Development
11.8 Teva pharmaceutical industries
11.8.1 Teva pharmaceutical industries Company Detail
11.8.2 Teva pharmaceutical industries Business Overview
11.8.3 Teva pharmaceutical industries Retinal Vascular Occlusion Introduction
11.8.4 Teva pharmaceutical industries Revenue in Retinal Vascular Occlusion Business (2018-2023)
11.8.5 Teva pharmaceutical industries Recent Development
11.9 Novo Nordisk
11.9.1 Novo Nordisk Company Detail
11.9.2 Novo Nordisk Business Overview
11.9.3 Novo Nordisk Retinal Vascular Occlusion Introduction
11.9.4 Novo Nordisk Revenue in Retinal Vascular Occlusion Business (2018-2023)
11.9.5 Novo Nordisk Recent Development
11.10 Sanofi
11.10.1 Sanofi Company Detail
11.10.2 Sanofi Business Overview
11.10.3 Sanofi Retinal Vascular Occlusion Introduction
11.10.4 Sanofi Revenue in Retinal Vascular Occlusion Business (2018-2023)
11.10.5 Sanofi Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details

Companies Mentioned:

Regeneron Pharmaceuticals, Inc.
Bayer HealthCare Pharmaceuticals LLC.
Novartis AG
Pfizer, Inc.
AstraZeneca PLC.
GlaxoSmithKline PLC.
Johnson & Johnson
Teva pharmaceutical industries
Novo Nordisk
Sanofi

License Types:

Single User License (PDF)

This license allows for use of a publication by one person.
This person may print out a single copy of the publication.
This person can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
This person cannot share the publication (or any information contained therein) with any other person or persons.
Unless a Enterprise License is purchased, a Single User License must be purchased for every person that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Site License (PDF)*

This license allows for use of a publication by all users within one corporate location, e.g. a regional office.
These users may print out a single copy of the publication.
These users can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
These users cannot share the publication (or any information contained therein) with any other person or persons outside the corporate location for which the publication is purchased.
Unless a Enterprise License is purchased, a Site User License must be purchased for every corporate location by an organization that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Global License (PDF)*

This license allows for use of a publication by unlimited users within the purchasing organization e.g. all employees of a single company.
Each of these people may use the publication on any computer, and may print out the report, but may not share the publication (or any information contained therein) with any other person or persons outside of the organization.
These employees of purchasing organization can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.

*If Applicable.